Insulin Receptor

Insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of tyrosine kinase receptors. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis, a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.
<table>
<thead>
<tr>
<th><strong>Insulin Receptor Inhibitors, Antagonists, Activators &amp; Modulators</strong></th>
</tr>
</thead>
</table>
| **AGL-2263**  
**Cat. No.: HY-112720**  
AGL-2263 is an insulin receptor (IR) blocker.  
Purity: 95.80%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg|
| **BMS-536924**  
**Cat. No.: HY-10262**  
BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM. IC50 value: 100 nM (IGF-1R); 73 nM (IR)  
Target: IGF-1R; IR in vitro  
BMS-536924 also inhibits FAK and Lck with IC50 of 150 nM and 341 nM, respectively.  
Purity: 99.74%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg|
| **BMS-754807**  
**Cat. No.: HY-10200**  
BMS-754807 is a potent and reversible inhibitor of IGF-1R/IR with IC50 of 1.8 and 1.7 nM, respectively and Ki of <2 nM for both, and also shows potent activities against Met, RON, TrkA, TrkB, AURA, and AURB with IC50 values of 6, 44, 7, 4, 9, and 25 nM, respectively.  
Purity: 99.76%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg|
| **Ceritinib**  
(LDK378)  
**Cat. No.: HY-15656**  
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib (LDK378) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively.  
Purity: 99.98%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg|
| **Ceritinib D7**  
(LDK378 D7)  
**Cat. No.: HY-15656S**  
Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 1 mg, 5 mg|
| **Ceritinib dihydrochloride**  
(LDK378 dihydrochloride)  
**Cat. No.: HY-15656A**  
Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM.  
Purity: 99.98%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg|
| **GSK1838705A**  
**Cat. No.: HY-13020**  
GSK1838705A is a potent and reversible IGF-IR and the insulin receptor inhibitor with IC50 of 2.0 and 1.6 nM, respectively. It also inhibits ALK with an IC50 of 0.5 nM.  
Purity: 98.99%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg|
| **Insulin levels modulator**  
**Cat. No.: HY-112819**  
Insulin levels modulator could be used to treat diabetes.  
Purity: >98%  
Clinical Data: No Development Reported  
Size: 100 mg, 250 mg, 500 mg|
| **Insulin(cattle)**  
(Insulin from bovine pancreas)  
**Cat. No.: HY-P1156**  
Insulin cattle (Insulin from bovine pancreas) is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.  
Purity: 98.60%  
Clinical Data: No Development Reported  
Size: 10 mg, 25 mg, 50 mg, 100 mg|
| **Insulin(human)**  
**Cat. No.: HY-P0035**  
Insulin(human) is a polypeptide hormone that regulates the level of glucose.  
Purity: 96.90%  
Clinical Data: Launched  
Size: 10 mg, 25 mg, 50 mg, 100 mg|

Tel: 609-228-6898  
Fax: 609-228-5909  
Email: sales@MedChemExpress.com
**Kaempferitrin**

Cat. No.: HY-N0628

Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates insulin signaling pathway.

| Purity: | 99.12% |
| Clinical Data: | No Development Reported |
| Size: | 10 mM × 1 mL, 1 mg, 5 mg, 10 mg |

**KU14R**

Cat. No.: HY-15481

KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

**Linsitinib**

Cat. No.: HY-10191

Linsitinib (OSI-906) is a dual inhibitor of the IGF-1 receptor and IR with IC\(_{50}\)s of 35 and 75 nM, respectively.

| Purity: | 99.90% |
| Clinical Data: | Phase 3 |
| Size: | 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

**MSDC 0160**

(Mitoglitazone, CAY10415)  
Cat. No.: HY-100550

MSDC 0160 act as an insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC), a key controller of cellular metabolism that influences mTOR (mammalian target of rapamycin) activation. In Vitro: MSDC-0160 acts as insulin sensitzers without activating PPARγ.

| Purity: | 99.40% |
| Clinical Data: | Phase 2 |
| Size: | 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg |

**NVP-AEW541**

(AEW541)  
Cat. No.: HY-50866

NVP-AEW541 is a potent inhibitor of IGF-1R with IC\(_{50}\) of 0.15 μM, also inhibits InsR, with IC\(_{50}\) of 0.14 μM.

| Purity: | >99.0% |
| Clinical Data: | No Development Reported |
| Size: | 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg |

**NVP-TAE 226**

(TAE226)  
Cat. No.: HY-13203

NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC\(_{50}\)s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC\(_{50}\)s of 3.5 nM and 44 nM, respectively.

| Purity: | 99.22% |
| Clinical Data: | No Development Reported |
| Size: | 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg |

**Rhoifolin**

Cat. No.: HY-N0755

Rhoifolin is a flavone glycoside isolated from Citrus grandis (L.) Osbeck leaves. Rhoifolin is beneficial for diabetic complications through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 5 mg, 10 mg, 20 mg |

**S961**

Cat. No.: HY-P2093

S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC\(_{50}\)s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |

**S961 TFA**

Cat. No.: HY-P2093A

S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC\(_{50}\)s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.

| Purity: | >98% |
| Clinical Data: | No Development Reported |
| Size: | 1 mg, 5 mg |